Top of the Street: Holcim, Buzzi, AstraZeneca

Nexans SA

20/11/2024 11:54

A round-up of notable broker activity this morning from Europe's
top-ranked* analysts:
    
    ** JPM shifts Holcim's  HOLN.S  rating from "neutral" to
"overweight", noting its attractive valuation despite its
year-to-date underperformance
    ** ** Buzzi  BZU.MI  gets an upgrade from "underweight" to
"neutral" by JPM, with potential U.S. infrastructure spending
benefits noted, though it's still not their top pick
    ** Amid China risks, UBS lifts AstraZeneca's  AZN.L  rating
from "sell" to "neutral", citing supportive government actions
and a bolstering 1.03x PharmaValues EV/NPV ratio
    
    INITIATIONS AND REINSTATEMENTS
    ** Berenberg begins its coverage of Avolta  AVOL.S  with a
"buy" rating, expecting it to surpass market growth by capturing
more share from smaller players
    ** Stifel restarts coverage on Prysmian  PRY.MI  with a
"buy" rating due to its diverse backlog and enhanced
high-voltage capacity 
    ** Stifel starts its coverage of Nexans  NEXS.PA  with a
"hold" rating, acknowledging it as a beneficiary of
electrification trends, albeit with a less versatile backlog and
future visibility
    
(*Analyst rankings from Thomson Reuters StarMine. The scale is
from 1-star to 5-star with 5 being the best. Analysts are ranked
on earnings accuracy as well as relative performance of
recommendations over trailing 12-month & 24-month periods.)


 (Reporting by Alessandro Parodi and Leo Marchandon)